We are studying the safety and effectiveness of Trastuzumab Deruxtecan in patients with advanced HER2-expressing tumors. This research aims to provide insights into new treatment possibilities for these patients.
Health conditions and diseases that the clinical trial is designed to study and treat.
HER2 Expressing Tumors are a type of cancer characterized by the overexpression of the HER2 protein, which can lead to aggressive tumor growth. These tumors are often found in breast cancer but can occur in other types as well.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
